To ask the Secretary of State for Health and Social Care, what steps he is taking to secure the supply of insulin from EU manufacturers after the transition period ends.
14 December 2020
Our priority is to ensure that patients continue to have access to the medicines they need, including insulin. We continue to work closely with the pharmaceutical industry, the National Health Service and others in the supply chain to deliver the shared goal of continuity of safe patient care by mitigating any potential disruption to supply into the United Kingdom of medicines at the end of the transition period.
As set out in a letter the Department sent to the pharmaceutical industry on 17 November 2020, we are implementing a multi-layered approach, that involves asking suppliers of medicines and medical products to the UK from or via the European Union to get trader ready, reroute their supply chains away from any potential disruption and stockpiling to a target level of six weeks on UK soil where this is possible. The letter is available at the following link: